Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Xuanyan Xu

Xuanyan Xu

Sr. Marketing Manager, Life Sciences Audience at Elsevier

Connect with Xuanyan Xu on LinkedIn
Follow Xuanyan Xu on Twitter
Website:

About the author: Seeing academic discoveries translated into life-changing applications is exciting--and, even more so, being a part of it. As a senior marketing manager for Life Sciences Audience, I bring a strong understanding of pharmaceutical industry needs, advancing technologies and customer insights to drive the product go-to-market strategy, planning and execution. Everything I write about here is geared towards issues that I deeply care about: open innovation, emerging approaches in data science and the evolving regulatory framework. Feel free to reach out to me about these topics. It is my desire to deliver my understanding and knowledge back to our communities.

Posts by Xuanyan Xu

Research Data Alliance Releases Guidelines for COVID-19 Data Sharing

Posted on July 24th, 2020 in COVID-19

The Research Data Alliance (RDA) has released its final version of the RDA COVID-19 Recommendations and Guidelines on data sharing for COVID-19, which covers four main research areas: clinical data, omics practices, epidemiology and social sciences. The document also touches on issues like community participation, legal and ethical considerations, research software and indigenous data.

(more…)

5 Ways RWE is Fueling the Fight Against COVID-19

Posted on June 19th, 2020 in COVID-19

As we discussed in an earlier blog post, real-world evidence can bring value to every stage of the drug life cycle, from early discovery to post-market. Now, as the worldwide research community continues to battle the COVID-19 pandemic, we are also discovering how real-world data and real-world evidence have something to offer in these efforts as well.

(more…)

How Are Regulatory Agencies Reacting to the Use of Real-World Evidence?

Posted on June 15th, 2020 in Pharma R&D

As we have discussed here previously, real-world data (RWD) and real-world evidence (RWE) offer many potential benefits in every stage of the drug discovery and development process, continuing on into post-market surveillance. With drug developers and other researchers becoming more interested in using RWD and the RWE that results from analyzing it, regulatory agencies have had to step up and work on producing guidance.

(more…)

Global networks form to take on the problem of drug-induced liver injury (DILI)

Posted on May 20th, 2020 in Pharma R&D

Drug-induced liver injury (DILI), which is one of the top causes of liver failure in the United States [1], is an adverse reaction that can be caused by a significant number of medications. DILI can be fatal and is not only a major concern post-market, but also during drug development as it is the top safety-related reason for late-stage clinical trial failure.

(more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 9